4MZ4

Discovery of an irreversible HCV NS5B polymerase inhibitor.

Zeng, Q., Nair, A.G., Rosenblum, S.B., Huang, H.C., Lesburg, C.A., Jiang, Y., Selyutin, O., Chan, T.Y., Bennett, F., Chen, K.X., Venkatraman, S., Sannigrahi, M., Velazquez, F., Duca, J.S., Gavalas, S., Huang, Y., Pu, H., Wang, L., Pinto, P., Vibulbhan, B., Agrawal, S., Ferrari, E., Jiang, C.K., Li, C., Hesk, D., Gesell, J., Sorota, S., Shih, N.Y., Njoroge, F.G., Kozlowski, J.A.

(2013) Bioorg Med Chem Lett 23: 6585-6587

• PubMed: 24252545 Search on PubMed
• DOI: https://doi.org/10.1016/j.bmcl.2013.10.060
• Primary Citation of Related Structures:  
  4MZ4


• PubMed Abstract: 
  

  The discovery of lead compound 2e was described. Its covalent binding to HCV NS5B polymerase enzyme was investigated by X-ray analysis. The results of distribution, metabolism and pharmacokinetics were reported. Compound 2e was demonstrated to be potent (replicon GT-1b EC50 = 0.003 μM), highly selective, and safe in in vitro and in vivo assays.

   View More

---

Organizational Affiliation: 

Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA.